CABA (Cabaletta Bio, Inc.) Forward P/E Multiple
Cabaletta Bio, Inc. (CABA) specializes in developing innovative therapies for immune pathologies. High business scalability allows the company to expand its products into the global market with minimal costs following technology patenting. The market capitalization trend on the GURU.Markets platform is currently at 0.00. Strong market positions are secured by stringent FDA requirements and colossal clinical trial costs, which create a significant barrier to entry for new players.
Analytical breakdowns for Cabaletta Bio, Inc.
- current price and projected stock value:
- business market valuation indicators:
- book capitalization information:
- debt and liquidity details:
- company profitability and valuation multiples indicators:
CABA - Net Profit|Projected Future Earnings Cabaletta Bio, Inc.|CABA - Price to Earnings Ratio|Forward P/E Multiple Cabaletta Bio, Inc|CABA - PEG Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Cabaletta Bio Inc.|CABA - Profit before payment of interest, taxes and amortization|Net earnings per share (EPS TTM) Cabaletta Bio, Inc.|CABA - Net earnings per one share for the last twelve months|Year-over-year net earnings per share growth for the last 12 months cabalettabio.com|CABA - Net earnings per one share growth for the current year|Expected earnings per share growth for next year Cabaletta Bio, Inc.
Summary company analytics:Cabaletta Bio
For Cabaletta Bio, Inc. (CABA), which is developing the CABA-201 platform in the field of immunotherapy, this indicator assesses market expectations for future success. The metric compares the current market value of the business with projected annual net income. By analyzing the forward P/E ratio for Cabaletta Bio, Inc. (CABA), an investor can determine the extent to which the price is inflated relative to fundamental forecasts. The upward trend of the curve reflects market optimism regarding clinical trials, allowing for the timely identification of speculative bubbles in the valuation of the biopharmaceutical asset.
Competitors of Cabaletta Bio, Inc. (CABA)
Projected Price to Earnings ARGX (argenx)|BNTX (BioNTech Inc.) - Future Price to Earnings Multiple|Forward P/E Multiple ABVX (abivax.com)|Market Cap to Projected Earnings ADMA Corp (ADMA)|PTGX - Future Price to Earnings|immunovant.com (IMVT) - Projected Price to Earnings|Kiniksa (KNSA) - Future Price to Earnings|Projected Price to Earnings Grifols SA|Projected Price to Earnings ADPT|Forward P/E Multiple Celldex Corp|Future Price to Earnings Aurinia Pharmaceuticals (AUPH)|biocryst.com - Price to Future Earnings Ratio|Forward P/E Multiple VERA (Vera Therapeutics)|Dianthus Therapeutics Inc (DNTH) - Projected Price to Earnings Ratio|Pharvaris Corp - Forward P/E Multiple|AbCellera Biologics (ABCL) - Projected Price to Earnings|TRML: Forward P/E Multiple|precigen.com (PGEN) - Forward P/E Multiple|PHAR (Pharming Group) - Forward P/E Multiple|Future Price to Earnings NKTR|Forward P/E Multiple UPB|Forward P/E Multiple Zenas Corp (ZBIO)|Future Price to Earnings Immunome, Inc. IMNM|gossamerbio.com - Future Price to Earnings|KalVista Pharmaceuticals, Inc. - Forward P/E Multiple|Projected Price to Earnings Ratio Septerna, Inc.|PVLA (Pieris Pharmaceuticals Inc) - Projected Price to Earnings|SVRA: Market Cap to Future Earnings Ratio|Projected Price to Earnings RIGL|ANAB (anaptysbio.com) - Market Cap to Future Earnings Ratio|Forward P/E Multiple ATXS|Forward P/E Multiple enGene Holdings Inc (ENGN)|RAPT Therapeutics, Inc. - Projected Price to Earnings|Future Price to Earnings Multiple JBIO|Aclaris Therapeutics - Forward P/E Multiple|KYTX: Future Price to Earnings|TLSA: Forward P/E Multiple|VTYX - Market Cap to Projected Earnings|Future Price to Earnings Theratechnologies Inc|Projected Price to Earnings Ratio Avalo Therapeutics Inc AVTX|Projected Price to Earnings ELDN (Eledon Pharmaceuticals)|AGEN (agenusbio.com) - Future Price to Earnings Multiple|Forward P/E Multiple CLYM (Climb Bio)|Market Cap to Projected Earnings Zura Bio Ltd (ZURA)|ATYR - Future Price to Earnings|ADAG (Adagene) - Price to Future Earnings Ratio|IMA: Forward P/E Multiple|Projected Price to Earnings Shattuck Labs|Projected Price to Earnings EQ|Connect Pharma (CNTB) - Market Cap to Projected Earnings|Forward P/E Multiple IMUX|Projected Price to Earnings atarabio.com ATRA|Forward P/E Multiple IFRX (InflaRx)|Forward P/E Multiple x4pharma.com XFOR|Adicet - Forward P/E Multiple|CELU: Future Price to Earnings|INMB: Forward P/E Multiple|Barinthus Biotherapeutics Corp (BRNS) - Forward P/E Multiple|Future Price to Earnings Kezar Life Sciences|sabbiotherapeutics.com - Price to Expected Earnings Ratio|Forward P/E Multiple AKTX|ENLV (enlivex.com) - Future Price to Earnings Multiple|Forward P/E Multiple QTTB (Q32 Bio)|Forward P/E Multiple GeoVax Corp GOVX|EDSA - Future Price to Earnings|Future Price to Earnings Multiple IBIO (ibioinc.com)|carismatx.com (CARM) - Future Price to Earnings|Projected Price to Earnings XTL Biopharmaceuticals Ltd|BOLT (Bolt Biotherapeutics Inc.) - Forward P/E Multiple|Forward P/E Multiple HCW Biologics Inc|Projected Price to Earnings APVO (Aptevo Therapeutics)|AIM (AIM ImmunoTech, Inc.) - Future Price to Earnings Multiple|Forward P/E Multiple ADTX (Aditxt, Inc.)|Market Cap to Projected Earnings GRI Bio Inc (GRI)|XRTX - Future Price to Earnings|Vyome Therapeutics (HIND) - Projected Price to Earnings|Revelation Biosciences (REVB) - Future Price to Earnings|Projected Price to Earnings indaptusrx.com|Projected Price to Earnings SCNI|Forward P/E Multiple CalciMedica Corp|Future Price to Earnings Affimed (AFMD)|allakos.com - Price to Future Earnings Ratio|Forward P/E Multiple HOOK (HOOKIPA Pharma)|IGM Biosciences Inc. (IGMS) - Projected Price to Earnings Ratio|iTeos Therapeutics, Inc. - Forward P/E Multiple|Ocean Biomedical Inc (OCEA) - Projected Price to Earnings|TCBP: Forward P/E Multiple|Third Harmonic Bio Inc (THRD) - Forward P/E Multiple
